Delayed BCG Immunotherapy After Transurethral Resection of Bladder Cancer Is Associated With Adverse Survival Outcomes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Delaying BCG Immunotherapy Onset After Transurethral Resection of Non-Muscle-Invasive Bladder Cancer Is Associated With Adverse Survival Outcomes
World J Urol 2020 Nov 23;[EPub Ahead of Print], W Krajewski, M Moschini, J Chorbińska, Ł Nowak, S Poletajew, A Tukiendorf, L Afferi, JY Teoh, T Muilwijk, S Joniau, A Tafuri, A Antonelli, F Cianflone, A Mari, E Di Trapani, K Hendricksen, M Alvarez-Maestro, A Rodríguez-Serrano, G Simone, S Zamboni, C Simeone, MC Marconi, R Mastroianni, G Ploussard, E Laukhtina, K Tully, A Kołodziej, J Krajewska, R Piszczek, E Xylinas, R ZdrojowyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.